ConductScience.org, home

Library / Genes

AXL: AXL receptor tyrosine kinase

1 protein, 139 patents, 7 drugs, 88 trials, 4,934 NIH grants and 9,928 papers.

Gene 7

Its symbol and name are HGNC's, unless HGNC and NCBI Gene contradict each other.

FieldValueSource
SymbolAXLHGNC
NameAXL receptor tyrosine kinaseHGNC
NCBI Gene ID558NCBI Gene
HGNC IDHGNC:905HGNC
EnsemblENSG00000167601NCBI Gene
AliasesARK, AXL3, JTK11, Tyro7, UFONCBI Gene
Typeprotein-codingNCBI Gene

Proteins 1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated inSource
P30530Tyrosine-protein kinase receptor UFO8944Ensembl, GeneID, HGNCUniProt

Patents 139

Patents whose sequence listing holds the protein exactly: the same sequence, by SHA-256, length and CRC-64. A sequence a patent lists is not always one it claims.

PublicationPublishedSEQ ID NOProteinSource
US 12552868 B22026-02-172P30530Espacenet
US 12545737 B22026-02-102P30530Espacenet
JP 2026502831 A2026-01-271P30530Espacenet
EP 4679095 A22026-01-142P30530Espacenet
KR 1020250180163 A2025-12-317P30530Espacenet
EP 4650780 A22025-11-194050P30530Espacenet
EP 4642794 A22025-11-051P30530Espacenet
EP 4641201 A22025-10-293619P30530Espacenet
EP 4633648 A12025-10-2275P30530Espacenet
JP 2025529142 A2025-09-04554P30530Espacenet

Drugs 7

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
BEMCENTINIBCHEMBL3809489Tyrosine-protein kinase receptor UFO inhibitorINHIBITORChEMBL
BPI-9016CHEMBL3545236Tyrosine-protein kinase receptor UFO inhibitorINHIBITORChEMBL
ENAPOTAMAB VEDOTINCHEMBL4297987Tyrosine-protein kinase receptor UFO binding agentBINDING AGENTChEMBL
GILTERITINIBCHEMBL3301622Tyrosine-protein kinase receptor UFO inhibitorINHIBITORChEMBL
GILTERITINIB FUMARATECHEMBL3301603Tyrosine-protein kinase receptor UFO inhibitorINHIBITORChEMBL
MECBOTAMAB VEDOTINCHEMBL5095312Tyrosine-protein kinase receptor UFO binding agentBINDING AGENTChEMBL
NINGETINIBCHEMBL3984441Tyrosine-protein kinase receptor UFO inhibitorINHIBITORChEMBL

Trials 88

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT07548710GILTERITINIBPHASE2ClinicalTrials.gov
NCT07535567BEMCENTINIBPHASE2/PHASE3ClinicalTrials.gov
NCT07463651GILTERITINIBPHASE3ClinicalTrials.gov
NCT07445048BEMCENTINIBPHASE3ClinicalTrials.gov
NCT07425808GILTERITINIBPHASE2/PHASE3ClinicalTrials.gov
NCT07407140GILTERITINIBPHASE3ClinicalTrials.gov
NCT07259707GILTERITINIBPHASE2ClinicalTrials.gov
NCT07140016GILTERITINIBPHASE1ClinicalTrials.gov
NCT07131059GILTERITINIBClinicalTrials.gov
NCT07032727GILTERITINIBPHASE2ClinicalTrials.gov

NIH grants 4934

NIH projects whose papers are about the gene, through NIH's grant-paper links.

ProjectTitleIts papers about the geneNewest fiscal yearSource
P30CA016672Cancer Center Support Grant1212,025NIH's project files
P30CA008748Cancer Center Support Grant932,025NIH's project files
P30CA046934University of Colorado Cancer Center Support Grant392,025NIH's project files
P30CA016058Cancer Center Support Grant282,025NIH's project files
P30CA010815Consolidated Basic Cancer Research Program262,025NIH's project files
P30CA076292Moffitt Cancer Center Support Grant212,025NIH's project files
P30CA006973Regional Oncology Research Center182,025NIH's project files
UL1TR001863Yale Clinical and Translational Science Award182,025NIH's project files
P30CA016359Cancer Center Support Grant162,025NIH's project files
P30CA042014Cancer Center Support Grant162,025NIH's project files

Papers 9928

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

PMIDFound bySource
42824075PubTator, text miningPubMed
42812889PubTator, text miningPubMed
42803451PubTator, text miningPubMed
42801717PubTator, text miningPubMed
42794437PubTator, text miningPubMed
42780548PubTator, text miningPubMed
42779833PubTator, text miningPubMed
42778661PubTator, text miningPubMed
42770830PubTator, text miningPubMed
42769717PubTator, text miningPubMed

The same record as JSON

Release gene-search-2026-11-11-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ChEMBL, through Open Targets: CC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

EMBL-EBI's patent proteins: EMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use

GenBank's patent files: GenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/

HGNC: CC0: https://www.genenames.org/about/license/

NCBI Gene: None named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/

NIH's project files and grant-paper links: Public domain (NIH RePORTER)

Open Targets: CC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

PubTator 3: Public domain

UniProt: CC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license